This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mohr, J. F.
Right arrow Articles by Ericsson, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mohr, J. F., III
Right arrow Articles by Ericsson, C. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2008, p. 1891-1893, Vol. 52, No. 5
0066-4804/08/$08.00+0     doi:10.1128/AAC.01321-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Pharmacokinetic Evaluation of Single-Dose Intravenous Daptomycin in Patients with Thermal Burn Injury{triangledown}

John F. Mohr III,1* Luis Ostrosky-Zeichner,1 David J. Wainright,2 Donald H. Parks,2 Timothy C. Hollenbeck,2 and Charles D. Ericsson1

Department of Internal Medicine, Division of Infectious Diseases,1 Department of Surgery, Division of Plastic Surgery, University of Texas Health Science Center, Houston, Texas2

Received 12 October 2007/ Returned for modification 11 November 2007/ Accepted 17 February 2008

Daptomycin pharmacokinetics were evaluated for burn patients. Burn patients had decreases in the maximum concentration of the drug in serum (44%) and the area under the concentration-time curve (47%) and increases in the volume of distribution (64%) and total clearance (77%) compared to healthy volunteers. In burn patients, daptomycin at 10 to 12 mg/kg of body weight/day would be required to achieve drug exposures similar to those for healthy volunteers receiving 6 mg/kg.

* Corresponding author. Mailing address: Division of Infectious Diseases, University of Texas Health Science Center at Houston, 6431 Fannin, MSB 2.112, Houston, Texas 77030. Phone: (713) 500-6742. Fax: (713) 500-5495. E-mail: john.mohr{at}uth.tmc.edu

{triangledown} Published ahead of print on 25 February 2008.

Antimicrobial Agents and Chemotherapy, May 2008, p. 1891-1893, Vol. 52, No. 5
0066-4804/08/$08.00+0     doi:10.1128/AAC.01321-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Dalley, A. J., Deans, R., Lipman, J., Venkatesh, B., Rudd, M., Roberts, M. S., Cross, S. E. (2009). Unbound Cephalothin Pharmacokinetics in Adult Burn Patients Are Related to the Elapsed Time after Injury. Antimicrob. Agents Chemother. 53: 5303-5305 [Abstract] [Full Text]  
  • Lovering, A. M., Le Floch, R., Hovsepian, L., Stephanazzi, J., Bret, P., Birraux, G., Vinsonneau, C. (2009). Pharmacokinetic evaluation of linezolid in patients with major thermal injuries. J Antimicrob Chemother 63: 553-559 [Abstract] [Full Text]  
  • Seaton, R. A. (2008). Daptomycin: rationale and role in the management of skin and soft tissue infections. J Antimicrob Chemother 62: iii15-iii23 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»